Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.49 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19872619 | 0.89 | MCL1 (0.55) | AKR1C3AKR1C2PTGS1TBXAS1KMO | |
| SCHEMBL20120108 | 0.86 | KDM4E (0.50) | AKR1C3AKR1C2PTGS1PLA2G4AKMO | |
| SCHEMBL18509545 | 0.84 | SPR (0.59) | AKR1C3AKR1C2PTGS1PLA2G4AEGFR | |
| SCHEMBL18509742 | 0.83 | PLA2G2A (0.48) | AKR1C3AKR1C2PTGS1TBXAS1PLA2G4A | |
| SCHEMBL18509730 | 0.83 | PLA2G4A (0.47) | AKR1C3AKR1C2PTGS1PLA2G4AOXER1 | |
| SCHEMBL6926561 | 0.83 | TACR1 (0.65) | TBXAS1TACR1 | |
| SCHEMBL12923717 | 0.82 | PLA2G4A (0.58) | AKR1C3AKR1C2PTGS1PLA2G4AEGFR | |
| SCHEMBL19872643 | 0.81 | EGFR (0.47) | AKR1C3AKR1C2PTGS1TBXAS1PLA2G4A | |
| SCHEMBL18271569 | 0.81 | AKR1C3 (0.64) | AKR1C3AKR1C2PTGS1 | |
| SCHEMBL18509702 | 0.81 | PLA2G4A (0.51) | AKR1C3AKR1C2TBXAS1PLA2G4AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019183358-A2 | WHOLE CELL PROCESSES TO PRODUCE NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20180044291-A1 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-02-15 | — | — | US | disclosed |
| WO-2016134145-A9 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044291-A1 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | CYP4F2, POR, CYP4F3 | AKR1C3 131/4885AKR1C2 224/4885PTGS1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.